J&J Paid $785 Million for a Look at Something That Has Never Been in a Human
J&J committed $785 million including a $465 million equity stake, plus an option to acquire Sail Biomedicines for $2.58 billion, on a preclinical in vivo CAR-T platform.
M&A
Dassault Paid $1.8B Cash for the Company That Processes 12 Million Safety Reports a Year
Dassault Systèmes will pay $1.8 billion cash for ArisGlobal, whose platform processes more than 12 million patient safety reports annually for 200 customers.
GSK Closed the Nuvalent Deal on 15 July. Seven Days Later, the FDA Approved the Drug.
GSK closed its Nuvalent acquisition on 15 July. The FDA approved Jideytro on 22 July, two months ahead of schedule, making it GSK’s first lung cancer drug.
Lilly’s Quiet $21B Sprint: Seven Deals, One Strategy Hiding in Plain Sight
While the industry debated whether GLP-1 mania had peaked, Eli Lilly closed seven acquisitions in 134 days.
February 2026 Deal Report: Five Signals from $53B in Activity
February 2026 recorded 218 biopharma transactions totalling $53B in disclosed value.
Lilly to buy Ventyx for $1.2B, bolstering oral inflammation pipeline
Lilly acquires Ventyx to expand oral inflammation pipeline.
Lilly in advanced talks to buy Ventyx in a deal topping $1B
Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1B, a move that would add inflammatory bowel disease and neurology assets.
BioMarin to Acquire Amicus for $4.8B in Rare Disease Deal
BioMarin will acquire Amicus Therapeutics for $4.8B in cash, adding Galafold and Pombiliti + Opfolda and accelerating rare-disease revenue growth.
Sobi Buys Arthrosi to Broaden Gout Franchise and Push Into Chronic Inflammation
Swedish orphan-drug specialist Sobi has agreed to acquire Arthrosi, a privately held biotech focused on next-generation gout therapies
Novo Nordisk Secures Breakthrough MASP-3 Asset in $2.1B Omeros Deal
Omeros has finalized the handoff of its clinical-stage MASP-3 monoclonal antibody zaltenibart (OMS906) to Novo Nordisk, closing a transaction that delivers immediate liquidity, removes near-term financing overhangs, and validates a complement-pathway mechanism increasingly viewed as one of the next competitive frontiers in immunology. The deal, first signed in mid-October, brings Omeros $240 million at closing … Read more